0
United States ( Change Country )

R547

Catalog No.S2688
Price
$ 470
$ 670
$ 1570
$ 3970
Availability

The item is temporarily out of stock. Please leave your email address and we will inform you when we have it in stock.

Just click the 'Arrival Notice' and leave your email address to get 10% off.

R547 Chemical Structure

Recommended Products

  • PD 0332991 HCl

    PD 0332991 is a highly selective inhibitor of Cdk4/cyclin D1 and Cdk6/cyclin D2 with IC50 of 11 nM and 16 nM, respectively.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) is a potent and selective cyclin-dependent kinases (CDK) 9, 7 and 2 inhibitor with IC50 of 4, 62 and 38 nM for CDK9, CDK2/cyclin A and CDK7/Cyclin H.

  • Roscovitine (Seliciclib, CYC202)

    Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective inhibitor of the cyclin-dependent kinases with IC50 of 0.65, 0.7, 0.7 and 0.16 μM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p53, respectively.

  • Flavopiridol (Alvocidib)

    Flavopiridol (Alvocidib) is a pan-cdk inhibitor. Flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC50 in the region of 100 nM) and tumour cell growth in vitro (typical IC50 in the region of 100 nM). Flavopiridol inhibited rhabdoid cell growth (IC50 of 200nmol/L).

  • JNJ-7706621

    JNJ-7706621 is a novel, potent, and broad-spectrum inhibitor of CDK and Aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B with IC50 of 9 nM, 4 nM, 3 nM and 11 nM, respectively.

  • PHA-793887

    PHA-793887 is a novel pan-cdk inhibitor, including cdk1, cdk2, cdk4, cdk5, cdk7, and cdk9 with IC50 in the 5 to 140 nM range.

  • AT7519

    AT7519 is a kinase inhibitor with IC50 of 0.19, 0.044, 0.51, 0.067, 0.66 and 0.018 μM for CDK1/cyclinB, CDK2/CyclinA, CDK2/Cyclin E, CDk4/CyclinD1, CDK6/Cyclin D3, CDk5/p35.

  • BS-181 HCl

    BS-181 is a highly selective cyclin-dependent kinase (CDK) inhibitor of CDK7 activity with IC50 of 21 nM.

  • Mubritinib (TAK 165)

    Mubritinib (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 μM, respectively

Biological Activity

R547 is a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases with a Ki of median 2 nM for CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1. In vivo, R547 showed antitumor activity. The selective kinase inhibition profile and the preclinical antitumor activity of R547 suggest that it may be promising for development for use in the treatment of solid tumors. The cyclin-dependent protein kinases are key regulators of cell cycle progression. Aberrant expression or altered activity of distinct cyclin-dependent kinase (CDK) complexes leads to escape of cells from cell cycle control, leading to unrestricted cell proliferation. CDK inhibitors have the potential to induce cell cycle arrest and apoptosis in cancer cells, and identifying small-molecule CDK inhibitors has been a major focus in cancer research. In cell-free assays, R547 was inactive (K(i) > 5,000 nM) against a panel of >120 unrelated kinases. In vitro, R547 effectively prevented the proliferation of tumor cell lines independent of multidrug resistant status, histologic type, retinoblastoma protein, or p53 status, with IC50 < 0.60 μM. [1]

References on R547
  • [1] Mol Cancer Ther. 2006 Nov;5(11):2644-58.
Molecular Weight (WM): 441.45
Formula:

C18H21F2N5O4S

CAS No.: 741713-40-6
Synonyms:
N/A
Dissolve in (25°C):  
 
 
Storage: 2 years-20°CPowder
1 week-4°Cin DMSO
1 month-80°in DMSO

Quality Control & MSDS

Research Area

Notes:

Related Inhibitors

Recommended Screening Libraries

Our scientific support team are available to answer any questions or queries.
Fill out an inquiry form for R547 for help.

Free Sample and Reward

We give free samples and rewards to people who would like to provide us useful scientific data(western blot, etc.) > See Details

Recently Viewed Items

Keywords:buy R547 | R547 supplier | purchase R547 | R547 cost | R547 manufacturer | order R547 | R547 distributor